Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
By including patients with acute myocardial infarction, mast cell markers were analyzed and the relationship between mast cells and patients with acute myocardial infarction was analyzed
Percutaneous coronary intervention (PCI) is the best way to improve the prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI). However, ischemia reperfusion injury, inappropriate ventricular remodeling, and myocardial fibrosis may still be present in STEMI after PCI, which may be related to the inflammatory response in STEMI. Mast cells (MC), their degranulation products and induction of a series of inflammatory cytokines play an important role in the inflammatory response. The purpose of this study was to evaluate the relationship between mast cell markers (trypsin, chymotrypsin) levels and prognosis after direct PCI in STEMI patients. We prospectively and continuously included STEMI patients undergoing standard therapy after direct PCI. Clinical data and blood samples were collected and followed up for 1 year to analyze mast cell markers and myocardial infarction size. As well as differences in echocardiography, markers of two-dimensional speck tracking techniques, inflammatory factors and major adverse cardiovascular events, to explore the relationship between mast cells and their products and ventricular remodeling and ischemia-reperfusion injury in STEMI patients, and to provide new ideas for treatment and new basis for optimization of STEMI treatment strategies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| STEMI | A total of 300 STEMI patients admitted to the Department of Cardiology, Peking University Third Hospital from April 1, 2023 to March 31, 2024 were enrolled. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tryptase | Diagnostic Test | Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa |
| Measure | Description | Time Frame |
|---|---|---|
| Myocardial infarct size | Myocardial infarct size was assessed by cardiac MRI | 3 months after myocardial infarction |
| Measure | Description | Time Frame |
|---|---|---|
| left ventricular systolic function | Transthoracic echocardiography to measure LVEF, left ventricular end-diastolic diameter, Em/Sm | 24 hours, 1 month, 3 months, and 12 months after myocardial infarction |
| Left ventricular ultrasound strain |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Three hundred STEMI patients who meet the inclusion criteria and do not meet the exclusion criteria admitted to the Department of Cardiovascular Medicine of Peking University Third Hospital were continuously recruited.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pengxin Xie | Contact | +8618810793282 | xiepengxin2014@163.com | |
| Ming Cui, Doctor | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Ming Cui | Peking University Third Hospital | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40103802 | Derived | Xie P, Xu S, Chen X, Xu H, Zhang R, Li D, Sun L, Zhu D, Cui M. Tryptase as a Biomarker for Adverse Prognosis in ST-Segment Elevation Myocardial Infarction Patients: A Prospective Cohort Study. J Inflamm Res. 2025 Mar 14;18:3817-3828. doi: 10.2147/JIR.S502496. eCollection 2025. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D000072657 | ST Elevation Myocardial Infarction |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009203 | Myocardial Infarction |
| D017202 | Myocardial Ischemia |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction
Two-dimensional speckle tracking imaging measures the movement in the long-axis direction as the overall longitudinal strain, the movement in the short-axis direction as the overall radial strain, reflecting the degree of wall systolic thickening, and the annular motion in the short-axis direction as the overall circumferential strain
| 24 hours, 1 month, 3 months, and 12 months after myocardial infarction |
| inflammatory marker such as TNF-α | 24 hours, 1 month, 3 months, and 12 months after myocardial infarction |
| inflammatory markers e.g. IL1, IL6 | 24 hours, 1 month, 3 months, and 12 months after myocardial infarction |
| MC marker (chymotrypsin) | 24 hours, 1 month, 3 months, and 12 months after myocardial infarction |
| major adverse cardiovascular events | MACE events (death, nonfatal myocardial infarction, unplanned revascularization, hospitalization for angina and readmission for heart failure) | 12 months |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D009336 | Necrosis |